GMAB News and Press, Genmab A/S From 11/04/21

Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody®-CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL) Poster presentation highlighting preliminary data from clinical trial evalua...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IBB. A list of cheap stocks. For further details see: IBB: Healthcare Dashboard For October

Mini-oral presentation highlighting data from first-in-human trial evaluating investigational bispecific antibody DuoBody ® -CD40×4-1BB (GEN1042) Poster presentation of clinical results from study evaluating investigational bispecific antibody DuoBody ® ...

According to a recent report from MarketsAndMarkets.com, the global Parkinson’s disease treatment market is expected to reach $5.69 billion by 2022, growing from $4.24 billion in 2017, expanding at a CAGR of 6.1%.  The report notes that this market is being driven by rising geriat...

TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells New Monotherapy Approved for Use in a Cancer with Limited Treatment Options Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN)...

- Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment - - Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging, Durable Anti-Tumor Activity in Previously Treated Patients - Seag...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

After the recent era of value expansion due to the pandemic and fiscal policy, the use of unbiased rankings may allow for long-term success. As valuations come back down to historical levels, as very few would claim they will stay elevated perpetually, holding the right stocks will be...

The biotech industry is making considerable progress in developing viable drugs and therapies for treating several critical diseases with the integration of advanced technologies. But although rising investments and breakthroughs in clinical trials make the industry’s prospects bright,...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September